Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection

Urbanowicz, Richard A.; Tsoleridis, Theocharis; Jackson, Hannah J.; Cusin, Lola; Duncan, Joshua D.; Chappell, Joseph G.; Tarr, Alexander W.; Nightingale, Jessica; Norrish, Alan R.; Ikram, Adeel; Marson, Ben; Craxford, Simon J.; Kelly, Anthony; Aithal, Guruprasad P.; Vijay, Amrita; Tighe, Patrick J.; Ball, Jonathan K.; Valdes, Ana M.; Ollivere, Benjamin J.

doi:10.1126/scitranslmed.abj0847

All Outputs (2)

Serum Levels of Proinflammatory Lipid Mediators and Specialized Proresolving Molecules Are Increased in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 and Correlate With Markers of the Adaptive Immune Response (2022)
Journal Article
Turnbull, J., Jha, R. R., Ortori, C. A., Lunt, E., Tighe, P. J., Irving, W. L., …Chapman, V. (2022). Serum Levels of Proinflammatory Lipid Mediators and Specialized Proresolving Molecules Are Increased in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 and Correlate With Markers of the Adaptive Immune Response. Journal of Infectious Diseases, 225(12), 2142-2154. https://doi.org/10.1093/infdis/jiab632

BACKGROUND: Specialized proresolution molecules (SPMs) halt the transition to chronic pathogenic inflammation. We aimed to quantify serum levels of pro- and anti-inflammatory bioactive lipids in severe acute respiratory syndrome coronavirus 2 (SARS-C... Read More about Serum Levels of Proinflammatory Lipid Mediators and Specialized Proresolving Molecules Are Increased in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 and Correlate With Markers of the Adaptive Immune Response.

Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection (2021)
Journal Article
Urbanowicz, R. A., Tsoleridis, T., Jackson, H. J., Cusin, L., Duncan, J. D., Chappell, J. G., …Ollivere, B. J. (2021). Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection. Science Translational Medicine, 13(609), Article eabj0847. https://doi.org/10.1126/scitranslmed.abj0847

Understanding the impact of prior infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on the response to vaccination is a priority for responding to the coronavirus disease 2019 (COVID-19) pandemic. In particular, it is necess... Read More about Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection.